Effects of Statins on Endothelial Progenitor Cell Proliferation from Peripheral Blood of Stable Coronary Artery Disease Patient
Abstract
Background: Atherosclerotic lesions develop as the result of an inflammatory process initiated by endothelial damage. Endothelial progrenitor cells (EPCs), which is derived from bone marrow, participate in endothelial repair and new vessel growth. Cardiovascular pharmacotherapies have been shown to improve overall numbers and function of EPCs in patients with cardiovascular risk and cardiovascular disease. Studies have reported that statins exert beneficial effects on EPCs by enhancing EPC proliferation and differentiation. Thus, we require a research to analyze the effects of three different statins on EPC proliferation. The objective of this study is to analyze the effect of statins on EPC proliferation from peripheral blood of stable coronary artery disease patient.
Methods: This is an in vitro true experimental post-test only control group design. The mononuclear cells (MNCs) were isolated from peripheral blood of stable coronary artery disease patient and were cultured in CFU-Hill medium for three days. Then samples were put into four groups, simvastatin experiment group, atorvastatin experiment group, rosuvastatin experiment group and control group. Each experiment group was divided into three subgroups with different doses, 0.1 ?mol/L, 0.5 ?mol/L, and 2.5 ?mol/L then incubated for 48 hours. EPC proliferation was evaluated afterwards with MTT cell proliferation assay. Immunocytochemistry method was performed for EPC identification to evaluate expression of CD34+. CFU-Hills were observed to confirm functional characteristics of EPC. Data were analyzed by independent T-test and ANOVA.
Results: MTT cell proliferation assay showed a significant increase of EPC proliferation in simvastatin, atorvastatin, and rosuvastatin groups compared with control group (0.237±0.007, 0.248±0.01, 0.231±0.008 vs 0.17±0.008, p<0.05). It also revealed significant difference in EPC proliferation between each experiment groups, which atorvastatin showed the highest effect. EPC proliferation in atorvastatin is higher than simvastatin group (0.248±0.01 vs. 0.237±0.007, p<0.05), and simvastatin is also higher than rosuvastatin group (0.237±0.007 vs. 0.231±0.008, p<0.05). CFU-Hill counts demonstrated highest number in rosuvastatin group, followed by atorvastatin, and simvastatin. Immunocytochemistry showed positive expression of CD34.
Conclusion: Statins increase EPC proliferation from peripheral blood of stable coronary artery disease patient. Atorvastatin showed the highest EPC proliferation, followed by simvastatin, and rosuvastatin. Each statins increased EPC proliferation dose-dependently.
Downloads
References
2. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol. 2010;55:1553-65.
3. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis. 2007;194(1):46-54.
4. Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2949-3003.
5. Du F, Zhou J, Gong R, Huang X. Endothelial progenitor cells in atherosclerosis. Front Biosci. 2012;17:2327-49.
6. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: Targeting cholesterol and inflammation in atherosclerosis. Eur Heart J. 2007;28:664-72.
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(3):39-43.
8. Zhou Q , James K. Liao. Statins and cardiovascular disease: From cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15(5):467-78.
9. Lee PSS, Kian K. Poh. Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells. 2014;6(3):355-66.
10. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. Journal Clin Invest. 2001;108:399-405.
11. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-90.
12. Spiel AO, Mayr FB, Leitner JM, et al. Simvastatin and rosuvastatin mobilize endothelial progenitor cells but do not prevent their acute decrease during systemic inflammation. Thrombosis Research. 2008;123:108-113.
13. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-7.
14. George AL, Prakash PB, Rajoria S, et al. Endothelial progenitor cell biology in disease and tissue regeneration. Journal of Hematology & Oncology 4. 2011.
15. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundamental & Clinical Pharmacology. 2004;19:117-25.
16. Shantsila E, Watson T, Tse HF, Lip GYH. Endothelial colony forming units: Are they a reliable marker of endothelial progenitor cell numbers? Annals of Medicine. 2007;39:474-9.
PDF downloads: 1814
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
